Step 1 topics → Hematology and Oncology → Thrombotic Thrombocytopenic Purpura (TTP)

Thrombotic Thrombocytopenic Purpura (TTP)

USMLE Step 1 trap: Misattributes TTP to excess vWF production rather than failure of ADAMTS13 to cleave ultra-large vWF multimers. TTP results from deficiency of ADAMTS13 (due to autoantibody or inherited mutation), causing accumulation of ultra-large vWF multimers that aggregate platelets in the microvasculature.

TTP is a thrombotic microangiopathy caused by ADAMTS13 deficiency — either from an autoantibody (acquired) or inherited mutation. USMLE Step 1 will test whether you understand this mechanism at the molecular level, not just that 'ADAMTS13 is low' — and the most dangerous wrong answer is transfusing platelets. In TTP, platelets are being consumed building microthrombi; giving more platelets accelerates that process and worsens ischemia to the kidneys and brain. Without functional ADAMTS13, ultra-large vWF multimers accumulate, spontaneously aggregate platelets, and form microthrombi throughout the vasculature, producing consumptive thrombocytopenia, MAHA, and end-organ damage simultaneously.

The exam hits TTP from three angles: mechanism (why does ADAMTS13 deficiency cause platelet aggregation?), presentation (what findings trigger empiric treatment?), and management (what do you do first, and what do you absolutely not do?). The pentad — microangiopathic hemolytic anemia, thrombocytopenia, fever, renal failure, neurologic changes — is classic board fodder, but the real trap is thinking you need all five to act. You don't. USMLE Step 1 will present a patient with just MAHA and thrombocytopenia and expect you to start plasma exchange immediately.

The two most dangerous misconceptions here are flipping the mechanism (excess vWF production vs. failure to cleave existing multimers) and thinking platelet transfusion is safe or helpful. In TTP, giving platelets is like throwing gasoline on the fire — you're supplying more substrate for the microthrombi that are destroying your patient's kidneys and brain. This is one of the hardest 'do NOT do this' items on the exam, and it trips up students who reflexively treat thrombocytopenia with platelets.

From real student decks
81%have cards covering this topic
57%have mature cards

Common misconceptions

Common mistake
Wrong: TTP results from excess vWF production rather than failure to cleave vWF multimers.
Right: TTP results from deficiency of ADAMTS13 (due to autoantibody or inherited mutation), causing accumulation of ultra-large vWF multimers that aggregate platelets in the microvasculature.
The problem in TTP is not that the body makes too much vWF — it's that the body fails to cut it down to size. ADAMTS13 normally cleaves ultra-large vWF multimers into smaller, less adhesive fragments. When ADAMTS13 is absent or inhibited, these giant multimers pile up and act as platelet flytraps under high-shear conditions in small vessels. Think of it as a scissors deficiency, not a vWF factory problem.
Common mistake
Wrong: Platelet transfusion is appropriate in TTP to treat the thrombocytopenia.
Right: Platelet transfusion is contraindicated in TTP because it provides substrate for further microvascular thrombosis, worsening end-organ damage.
Platelet transfusion is one of the few true contraindications in medicine, and TTP is the classic example. The thrombocytopenia in TTP isn't from inadequate production — platelets are being consumed building microthrombi. Giving more platelets accelerates that process, worsening ischemia to the kidneys and brain. The mnemonic is: 'platelets in TTP = fuel on the fire.'
Common mistake
Wrong: All five elements of the classic pentad must be present to diagnose TTP and initiate plasma exchange.
Right: The full pentad (MAHA, thrombocytopenia, fever, renal failure, neurologic changes) is present in fewer than 40% of cases; MAHA plus thrombocytopenia alone is sufficient to initiate plasma exchange empirically.
The full pentad is a teaching tool, not a diagnostic checklist. In clinical practice — and on Step 1 — waiting for all five features delays life-saving treatment. MAHA (schistocytes on smear, elevated LDH, low haptoglobin) plus unexplained thrombocytopenia is enough to start plasma exchange empirically. The risk of delaying treatment far outweighs the risk of treating a mimic.
Common mistake
Wrong: Fresh frozen plasma infusion is equivalent to plasma exchange in treating TTP.
Right: Plasma exchange (plasmapheresis) is superior to FFP infusion alone because it both removes the anti-ADAMTS13 antibody and replaces functional ADAMTS13.
FFP infusion replaces ADAMTS13, which is helpful. But plasma exchange does two things simultaneously: it removes the pathogenic anti-ADAMTS13 autoantibody AND replenishes functional ADAMTS13. FFP infusion alone can't clear the antibody, so it's inferior and insufficient as monotherapy. This distinction is exactly the kind of mechanistic nuance USMLE Step 1 rewards.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Mechanism: Know that TTP results from ADAMTS13 deficiency (autoantibody or inherited) leading to accumulation of ultra-large vWF multimers that spontaneously aggregate platelets in small vessels — not from excess vWF production.
  2. Presentation: Recognize the classic pentad (MAHA, thrombocytopenia, fever, renal failure, neurologic changes), but know that fewer than 40% of patients have all five — MAHA plus thrombocytopenia alone is sufficient to diagnose TTP presumptively and start treatment.
  3. Management: Identify plasma exchange (plasmapheresis) as first-line therapy, understand why it works (removes anti-ADAMTS13 antibody AND replaces functional ADAMTS13), and recognize that platelet transfusion is contraindicated because it worsens microvascular thrombosis.

Can you avoid these mistakes?

A 32-year-old woman presents with confusion, a platelet count of 18,000/µL, schistocytes on peripheral smear, elevated LDH, and low haptoglobin. Temperature is 37.8°C and creatinine is 1.1 mg/dL. What is the next best step in management?
Why is platelet transfusion contraindicated in TTP, even when the platelet count is critically low? What specific harm does it cause?
A patient is diagnosed with TTP. The intern suggests starting FFP infusion instead of plasma exchange because 'it's easier to set up.' What critical limitation does FFP infusion have compared to plasma exchange?
At the molecular level, explain how ADAMTS13 deficiency leads to platelet microthrombi. What is the specific substrate that accumulates, and what does it do to platelets?

Related topics

Platelet Physiology and Primary Hemostasis Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function

See how your Anki deck covers this topic.

Upload your deck for a free audit →